Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PGK1 | P00558 | 2/20 | 0.56 |
| ▸ | PGK2 | P07205 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18372459 | 1.00 | KDM4E (0.57) | KDM4EPKMPGK1PGK2LMNA | |
| SCHEMBL18371513 | 1.00 | KDM4E (0.57) | KDM4EPKMPGK1PGK2LMNA | |
| SCHEMBL28120773 | 0.86 | KDM4E (0.64) | KDM4EPKMPGK1PGK2ADORA3 | |
| SCHEMBL3692106 | 0.86 | ADORA3 (0.74) | KDM4EPKMADORA3ADORA1ADORA2A | |
| SCHEMBL1961097 | 0.86 | ADORA3 (0.74) | KDM4EPKMADORA3ADORA1ADORA2A | |
| SCHEMBL40851 | 0.86 | PGK1 (0.60) | KDM4EPKMPGK1PGK2ADORA3 | |
| SCHEMBL29389303 | 0.86 | PGK1 (0.60) | KDM4EPKMPGK1PGK2ADORA3 | |
| SCHEMBL8818497 | 0.85 | KDM4E (0.59) | KDM4EPKMPGK1PGK2ADORA3 | |
| SCHEMBL28952609 | 0.85 | KDM4E (0.59) | KDM4EPKMPGK1PGK2ADORA3 | |
| SCHEMBL546736 | 0.84 | PGK1 (0.60) | KDM4EPKMPGK1PGK2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025091594-A1 | METHOD FOR PREPARING SINGLE-STRANDED RNA-DNA CHIMERA | 清华大学 | 2025-05-08 | — | — | WO | claimed |
| CN-119932137-A | Method for preparing single-stranded RNA-DNA chimera | 清华大学 | 2025-05-06 | — | — | CN | claimed |
| WO-2025075256-A1 | APPARATUS AND METHOD FOR EARLY DISEASE DETECTION BASED ON HIGH-DEPTH CELL-FREE NUCLEIC ACID SEQUENCING | (주)지놈포미 | 2025-04-10 | — | — | WO | claimed |
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025038971-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038960-A1 | OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-11866704-B2 | Nucleic acid molecules and uses thereof | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-01-09 | — | — | US | claimed |
| WO-2023141474-A9 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2023141474-A1 | POLY-TAILED AND POLY-CAPPED MRNA AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| WO-2022247943-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2022-12-01 | — | — | WO | claimed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | claimed |
| WO-2022241045-A1 | MODIFIED MRNA, MODIFIED NON-CODING RNA, AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022212711-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | MODERNATX, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3889602-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2021-10-06 | — | — | EP | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | KDM4E 4693/4885PKM 2630/4885PGK1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.